Oak Ridge Investments LLC Reduces Position in Insmed, Inc. $INSM

Key Points

• Oak Ridge Investments LLC decreased its stake in Insmed, Inc. by 25.9%, now holding 41,945 shares valued at $3.2 million following a sale of 14,691 shares.
• Several hedge funds have increased their positions in Insmed during the first quarter, with Cullen Frost Bankers Inc. notably raising its holdings by 164.9%.
• Insmed reported a quarterly earnings miss of ($1.70) EPS, falling short of the consensus estimate of ($1.30) despite a revenue increase of 18.9% year-over-year.

Oak Ridge Investments LLC reduced its holdings in Insmed, Inc. (NASDAQ:INSM - Free Report) by 25.9% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 41,945 shares of the biopharmaceutical company's stock after selling 14,691 shares during the period. Oak Ridge Investments LLC's holdings in Insmed were worth $3,200,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Cullen Frost Bankers Inc. lifted its holdings in shares of Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 221 shares during the last quarter. Elequin Capital LP bought a new stake in Insmed during the 4th quarter valued at about $28,000. NBC Securities Inc. bought a new stake in Insmed during the 1st quarter valued at about $49,000. Versant Capital Management Inc lifted its holdings in Insmed by 546.3% during the 1st quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 590 shares in the last quarter. Finally, Signaturefd LLC lifted its holdings in Insmed by 60.0% during the 1st quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock valued at $66,000 after buying an additional 325 shares in the last quarter.

Insmed Stock Performance

NASDAQ:INSM traded up $0.77 during trading hours on Tuesday, hitting $128.04. 871,098 shares of the company were exchanged, compared to its average volume of 2,825,287. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $130.13. The company's 50 day moving average price is $104.75 and its 200-day moving average price is $84.33. The stock has a market capitalization of $27.07 billion, a price-to-earnings ratio of -22.42 and a beta of 0.95.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. During the same quarter in the previous year, the firm posted ($1.94) earnings per share. The business's revenue was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current year.

Wall Street Analyst Weigh In

INSM has been the subject of a number of research analyst reports. Mizuho lifted their price objective on shares of Insmed from $130.00 to $165.00 and gave the company an "outperform" rating in a report on Wednesday, August 13th. Royal Bank Of Canada boosted their price target on shares of Insmed from $108.00 to $120.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Jefferies Financial Group boosted their price target on shares of Insmed from $129.00 to $148.00 and gave the company a "buy" rating in a report on Wednesday, August 13th. Citigroup upgraded shares of Insmed to a "buy" rating in a report on Tuesday, June 10th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Insmed from $90.00 to $111.00 and gave the company an "overweight" rating in a report on Tuesday, July 8th. Fifteen equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $129.57.

Insider Activity

In related news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the business's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $93.42, for a total value of $9,264,648.24. Following the completion of the transaction, the insider directly owned 89,407 shares in the company, valued at $8,352,401.94. The trade was a 52.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director David W. J. Mcgirr sold 3,250 shares of the company's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $71.30, for a total transaction of $231,725.00. Following the transaction, the director owned 100,723 shares of the company's stock, valued at $7,181,549.90. This represents a 3.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 497,829 shares of company stock valued at $47,778,638. 3.00% of the stock is currently owned by company insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.